期刊文献+

浅谈卵巢癌的个体化治疗

Study on Individualized Treatment On Patient With Ovarian Cancer
下载PDF
导出
摘要 卵巢癌是妇科常见的肿瘤之一,其发病率仅次于子宫颈癌和子宫体癌,而列居第三,但其至死率却占首位,成为严重威胁妇女生命的肿瘤。卵巢癌个体化治疗是根据患者的具体情况,选择适宜患者的手术和药物治疗方案,从而达到最有利于患者的治疗效果。笔者从哲学的角度对卵巢癌个体化治疗的依据、认识和措施进行综合分析。 Ovarian cancer is one of the commonent gynecologic tumor, its incidence just after cervical cancer and carcinoma of endometrium, as the third. But it's mortality rate is the highest, and endanger womens' health seriously. Individualized treatment is the optimal treatment on patient with ovarian cancer, which chose surgical and drug treatment project according to specific condition of patient. To analyse the foundation, the recognition and the method of individualized treatment with a philospophical view.
出处 《医学与社会》 2006年第4期49-51,共3页 Medicine and Society
关键词 卵巢癌 治疗 个体化 ovarian cancer treatment individualization
  • 相关文献

参考文献6

二级参考文献52

  • 1曹泽毅,于莎莎.妇科恶性肿瘤治疗后一年内未控与复发原因的研究——附全国61所医院1753例分析[J].中华妇产科杂志,1996,31(7):417-421. 被引量:21
  • 2NgI W, Rubin, SC. Hosiins WJ. et al. Aggressive chemosurgial debulking in patients with advanced ovarian cancer[ J]. Gynecol Oncol, 1990,38:358.
  • 3Zylberbery B, Ravine JH, Salat-broux J. et al. Chemotherapy by the intravenous and intraperitoneal routes combined in ovarian cancer[J].Gyneco Oncol, 1997,65 : 164.
  • 4Richard DE, Berra E, Pouysségur J. Angiogenesis: How a tumor adapts to hypoxia[J].Biochem Biophys Res Commun,1999,266:718-722.
  • 5Nakayama K, Kanzaki A, Hata K, et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma[J].Cancer Lett,2002,176:215-223.
  • 6海春旭.自由基生物学和抗氧化剂研究进展[M].西安:旅游出版社,1999..
  • 7Werner T. Computer-assisted analysis of transcription control regions. Matinspector and other programs[J].Methods Mol Biol,2000,132:337-349.
  • 8Knowles HJ,Harris AL.Hypoxia and oxidative stress in breast cancer:Hypoxia and tumourigenesis[J].Breast Cancer Res,2001,3:318-322.
  • 9Coulet F,Nadaud S,Agrapart M,et al.Identification of hypoxia-response element in the human endothelial nitri-oxide synthase gene promoter[J].J Biol Chem,2003,278:46230-46240.
  • 10Bolis G, Scarfone G, Giardina G, et al. Carboplatin alone versus carboplatin plus epidoxorubicin as second-line therapy for cisplatin or carboplatin sensitve ovarian cancer[J]. Gynecol Oncol,2001, 81(1): 3-9

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部